Meyer J, et al. - Researchers assessed the toxicity of combining bavituximab (an antibody that targets exposed phosphatidylserine) with capecitabine and radiation therapy in treating rectal carcinoma. They enrolled patients with stage II or III rectal adenocarcinoma in a phase I study combining radiation therapy, capecitabine, and bavituximab. Findings indicated the safety of bavituximab in combination with capecitabine and radiation therapy at the doses selected for the study. A grade III infusion reaction related to bavituximab was experienced by one patient at the highest dose level. A complete pathologic response to the combination treatment was seen in one tumor.